|Dr. Selwyn Ho MB BS, MBBS||CEO & Member of Executive Management Board||384.47k||N/A||1971|
|Dr. Dolores J. Schendel||Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development||600k||N/A||N/A|
|Dr. Ernst-Ludwig Winnacker||Co-Founder & Chairman Scientific Advisory Board||20k||N/A||1941|
|Dr. Birger Kohlert||Chief Financial Officer||N/A||N/A||N/A|
|Pamela Keck||Vice President of Investor Relations & Corporate Communications||N/A||N/A||N/A|
|Dr. Kirsty Crame M.D.||VP and Head of Clinical Research & Development||N/A||N/A||N/A|
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.
Medigene AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.